Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Industries
Nr. of Employees
small (1-50)
Products
GMAB Technology
A non-viral, cell-penetrating antibody technology designed to deliver nucleic acid payloads directly into cells, targeting specific diseases like cancer and skeletal muscle disorders.
GMAB ADC for Solid Tumors
A specific application of GMAB technology as an antibody-drug conjugate targeting solid tumors, demonstrated to deliver cytotoxic drugs directly to tumor cells in preclinical studies.
GMAB Technology
A non-viral, cell-penetrating antibody technology designed to deliver nucleic acid payloads directly into cells, targeting specific diseases like cancer and skeletal muscle disorders.
GMAB ADC for Solid Tumors
A specific application of GMAB technology as an antibody-drug conjugate targeting solid tumors, demonstrated to deliver cytotoxic drugs directly to tumor cells in preclinical studies.